DFO
VRTX icon

Duquesne Family Office’s Vertex Pharmaceuticals VRTX Stock Holding History

Duquesne Family Office’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-146,600
Closed -$16.5M – 44
2014
Q3 		$16.5M Buy
+146,600
New +$14M 2.02% 20

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Duquesne Family Office's VRTX Position: Q4 2014 in Review

Duquesne Family Office sold out of Vertex Pharmaceuticals (VRTX) in Q4 2014, closing a stake of 146,600 shares — an estimated $16.5M sold.

Duquesne Family Office first reported a position in VRTX in Q3 2014 and held it in 1 quarter. The position peaked at $16.5M in Q3 2014. 475 funds tracked by Wall St. Rank hold VRTX as of Q4 2014.

  • Duquesne Family Office reported no remaining Vertex Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Duquesne Family Office sold 146,600 Vertex Pharmaceuticals shares in Q4 2014, an estimated $16.5M.
  • Duquesne Family Office first reported a position in Vertex Pharmaceuticals in Q3 2014 and held it in 1 quarter.
  • Duquesne Family Office's Vertex Pharmaceuticals position peaked at $16.5M in Q3 2014.
  • 475 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2014.

Based on Duquesne Family Office's 13F filing for Q4 2014, filed 12 Feb 2015.